CAN FITE BIOPHARMA LTD-ADR (CANF) Stock Price & Overview

NYSEARCA:CANF • US13471N3008

Current stock price

3.6 USD
-0.12 (-3.23%)
At close:
3.56 USD
-0.04 (-1.11%)
After Hours:

The current stock price of CANF is 3.6 USD. Today CANF is down by -3.23%. In the past month the price decreased by -16.67%. In the past year, price decreased by -88.96%.

CANF Key Statistics

52-Week Range3.356 - 46.6
Current CANF stock price positioned within its 52-week range.
1-Month Range3.53 - 10.4
Current CANF stock price positioned within its 1-month range.
Market Cap
4.713M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-9.44
Dividend Yield
N/A

CANF Stock Performance

Today
-3.23%
1 Week
-20.88%
1 Month
-16.67%
3 Months
-36.35%
Longer-term
6 Months -72.71%
1 Year -88.96%
2 Years -91.89%
3 Years -92.14%
5 Years -99.27%
10 Years -99.96%

CANF Stock Chart

CAN FITE BIOPHARMA LTD-ADR / CANF Daily stock chart

CANF Technical Analysis

ChartMill assigns a technical rating of 0 / 10 to CANF. When comparing the yearly performance of all stocks, CANF is a bad performer in the overall market: 96.91% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

CANF Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to CANF. The financial health of CANF is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

CANF Earnings

Next Earnings DateApr 12, 2026
Last Earnings DateN/A
PeriodQ2 / 2025
EPS Reported
Revenue Reported
EPS Surprise %
Revenue Surprise %

CANF Forecast & Estimates


Analysts
Analysts80
Price TargetN/A
EPS Next Y13.95%
Revenue Next Year0%

CANF Groups

Sector & Classification

Sub-Industry
Biotechnology
Index Membership

CANF Financial Highlights

Over the last trailing twelve months CANF reported a non-GAAP Earnings per Share(EPS) of -9.44. The EPS increased by 39.36% compared to the year before.


Income Statements
Revenue(TTM)674.00K
Net Income(TTM)-7.88M
Industry RankSector Rank
PM (TTM) N/A
ROA -102.07%
ROE -188.34%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%34.22%
Sales Q2Q%-36.08%
EPS 1Y (TTM)39.36%
Revenue 1Y (TTM)-9.29%

CANF Ownership

Ownership
Inst Owners2.01%
Shares1.31M
Float1.31M
Ins Owners0.01%
Short Float %6.89%
Short Ratio0.02

CANF Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
ABBV ABBVIE INC14.8398.492B
AMGN AMGEN INC16.04198.265B
GILD GILEAD SCIENCES INC16.4180.267B
VRTX VERTEX PHARMACEUTICALS INC24.21121.459B
REGN REGENERON PHARMACEUTICALS15.9578.932B
ALNY ALNYLAM PHARMACEUTICALS INC42.0142.071B
INSM INSMED INC N/A30.073B
BIIB BIOGEN INC11.2927.136B
NTRA NATERA INC N/A26.973B
UTHR UNITED THERAPEUTICS CORP17.9523.353B
MRNA MODERNA INC N/A21.086B
EXAS EXACT SCIENCES CORP340.7419.713B
RVMD REVOLUTION MEDICINES INC N/A18.84B

About CANF

Company Profile

CANF logo image Can-Fite BioPharma Ltd. is a biopharmaceutical company, which engages in the development of drugs for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The firm co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. Its technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.

Company Info

IPO: 2005-09-22

CAN FITE BIOPHARMA LTD-ADR

10 Bareket Street, Kiryat Matalon, P.O. Box 7537

Petah Tikva 4951778 IL

CEO: Pnina Fishman

Employees: 5

CANF Company Website

CANF Investor Relations

Phone: 97239241114

CAN FITE BIOPHARMA LTD-ADR / CANF FAQ

Can you describe the business of CAN FITE BIOPHARMA LTD-ADR?

Can-Fite BioPharma Ltd. is a biopharmaceutical company, which engages in the development of drugs for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The firm co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. Its technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.


What is the stock price of CAN FITE BIOPHARMA LTD-ADR today?

The current stock price of CANF is 3.6 USD. The price decreased by -3.23% in the last trading session.


What is the dividend status of CAN FITE BIOPHARMA LTD-ADR?

CANF does not pay a dividend.


How is the ChartMill rating for CAN FITE BIOPHARMA LTD-ADR?

CANF has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


What is the market capitalization of CANF stock?

CAN FITE BIOPHARMA LTD-ADR (CANF) has a market capitalization of 4.71M USD. This makes CANF a Nano Cap stock.


What is the Short Interest ratio of CAN FITE BIOPHARMA LTD-ADR (CANF) stock?

The outstanding short interest for CAN FITE BIOPHARMA LTD-ADR (CANF) is 6.89% of its float.